Cometriq Approved for Rare Thyroid Cancer

Drug designed to inhibit tumor growth

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

THURSDAY, Nov. 29, 2012 (HealthDay News) -- Cometriq (cabozantinib) has been approved by the U.S. Food and Drug Administration to treat medullary thyroid cancer that has spread to other parts of the body, the agency said Thursday.

The medullary form accounts for about 4 percent of the more than 56,000 cases of thyroid cancer diagnosed annually in the United States, the FDA said in a news release. This type of cancer develops in thyroid cells that produce a hormone that helps regulate blood calcium.

Cometriq is a kinase inhibitor that's designed to block the effects of proteins involved in cancer cell development and growth. People should not eat at least two hours before, and one hour after, taking the drug, the agency said.

Cometriq's safety and effectiveness were evaluated in clinical studies involving 330 people with medullary thyroid cancer. Those given Cometriq lived an average of 11.2 months without tumor growth, compared with an average of four months among people who took a placebo. The drug "did not extend patients' lives," the FDA said.

The product's label has a boxed warning of the potential for severe and fatal bleeding of the colon, the FDA said.

More common and less serious side effects may include diarrhea, mouth sores, redness and swelling of the fingers or toes, weight loss, appetite suppression and nausea.

Cometriq is marketed by Exelixis, based in San Francisco.

More information

The U.S. National Library of Medicine has more about medullary thyroid cancer.


Last Updated: